AzTrials
AzTrials

Advanced Parkinson's DiseasePhase 3NCT00335153

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

A Phase 3 study testing Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump and PEG tube in people with Advanced Parkinson's Disease, run by AbbVie (prior sponsor, Abbott) at 83 sites in 16 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations. Read more about this study

Who is it for?
Ages 30 years and older
Conditions the study is for
Advanced Parkinson's Disease
What is being tested?
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump and PEG tube
Could I receive a placebo?
No, everyone receives an active treatment
How many people
354 participants
Where
83 sitesin 16 countries
Study dates
Jan 2008to Jun 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
  • Levodopa-responsive with severe motor fluctuations
  • Recognizable off and on state (motor fluctuations) confirmed by diary

Who cannot join

  • Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as secondary parkinsonism
  • Undergone surgery for the treatment of PD
  • Contraindications to levodopa (such as narrow angle glaucoma)

Trial locations and contacts

83 sites in 16 countries.

83 sites in 16 countries

United States31 sites
  • Site Reference ID/Investigator# 50062

    Augusta, Georgia, 30912

  • Site Reference ID/Investigator# 50080

    Baltimore, Maryland, 21201

  • Site Reference ID/Investigator# 50074

    Baltimore, Maryland, 21287

  • Site Reference ID/Investigator# 50065

    Birmingham, Alabama, 35222

  • Site Reference ID/Investigator# 50077

    Bradenton, Florida, 34205

  • Site Reference ID/Investigator# 50058

    Burlington, Vermont, 05401

  • Site Reference ID/Investigator# 50050

    Chicago, Illinois, 60611

  • Site Reference ID/Investigator# 50078

    Chicago, Illinois, 60612

  • Site Reference ID/Investigator# 50043

    Cincinnati, Ohio, 45267

  • Site Reference ID/Investigator# 50044

    Cleveland, Ohio, 44195-0001

  • Site Reference ID/Investigator# 50061

    Englewood, Colorado, 80113

  • Site Reference ID/Investigator# 50060

    Fort Lauderdale, Florida, 33308

  • Site Reference ID/Investigator# 50059

    Fountain Valley, California, 92708

  • Site Reference ID/Investigator# 50049

    Gainesville, Florida, 32610

  • Site Reference ID/Investigator# 50047

    Jacksonville, Florida, 32209

  • Site Reference ID/Investigator# 50045

    Kirkland, Washington, 98034

  • Site Reference ID/Investigator# 50064

    Lexington, Kentucky, 40536

  • Site Reference ID/Investigator# 50048

    Los Angeles, California, 90033

  • Site Reference ID/Investigator# 50072

    Manhasset, New York, 11030

  • Site Reference ID/Investigator# 50070

    Milwaukee, Wisconsin, 53226

  • Site Reference ID/Investigator# 50067

    New York, New York, 10029

  • Site Reference ID/Investigator# 50066

    New York, New York, 10032

  • Site Reference ID/Investigator# 50076

    Oceanside, California, 92056

  • Site Reference ID/Investigator# 50042

    Omaha, Nebraska, 68198-2045

  • Site Reference ID/Investigator# 50068

    Port Charlotte, Florida, 33890

  • Site Reference ID/Investigator# 50069

    Raleigh, North Carolina, 27607

  • Site Reference ID/Investigator# 50075

    Shreveport, Louisiana, 71103

  • Site Reference ID/Investigator# 50073

    St Louis, Missouri, 63110

  • Site Reference ID/Investigator# 50046

    Tampa, Florida, 33613

  • Site Reference ID/Investigator# 50079

    Washington D.C., District of Columbia, 20007

  • Site Reference ID/Investigator# 50063

    Winston-Salem, North Carolina, 27157

Other trials in United States

Germany7 sites
  • Site Reference ID/Investigator# 48028

    Berlin, 12200

  • Site Reference ID/Investigator# 48029

    Berlin, 13088

  • Site Reference ID/Investigator# 48036

    Freiburg im Breisgau, 79106

  • Site Reference ID/Investigator# 48034

    Göttingen, 37075

  • Site Reference ID/Investigator# 48022

    Hanau, 63450

  • Site Reference ID/Investigator# 48024

    Hanover, 30625

  • Site Reference ID/Investigator# 48035

    Mainz, 55131

Other trials in Germany

Italy6 sites
  • Site Reference ID/Investigator# 50131

    Arcugnano, 36057

  • Site Reference ID/Investigator# 50132

    Catania, 95125

  • Site Reference ID/Investigator# 50128

    Genoa, 16132

  • Site Reference ID/Investigator# 50129

    Lido di Camaiore, 55043

  • Site Reference ID/Investigator# 50130

    Naples, 80131

  • Site Reference ID/Investigator# 50127

    Rome, 00163

Other trials in Italy

Russia6 sites
  • Site Reference ID/Investigator# 50143

    Kazan', 420061

  • Site Reference ID/Investigator# 50141

    Moscow, 125367

  • Site Reference ID/Investigator# 50145

    Saint Petersburg, 193312

  • Site Reference ID/Investigator# 50142

    Saint Petersburg, 194044

  • Site Reference ID/Investigator# 50147

    Saint Petersburg, 197089

  • Site Reference ID/Investigator# 50146

    Saint Petersburg, 197706

Other trials in Russia

Czechia5 sites
  • Site Reference ID/Investigator# 46436

    Brno, 65691

  • Site Reference ID/Investigator# 46438

    Hradec Králové, 500 05

  • Site Reference ID/Investigator# 46435

    Pardubice, 532 03

  • Site Reference ID/Investigator# 46437

    Prague, 128 08

  • Site Reference ID/Investigator# 46439

    Prague, 15006

Other trials in Czechia

Spain5 sites
  • Site Reference ID/Investigator# 50154

    Barcelona, 08003

  • Site Reference ID/Investigator# 50152

    Barcelona, 08025

  • Site Reference ID/Investigator# 50202

    Barcelona, 08035

  • Site Reference ID/Investigator# 50155

    Barcelona, 08036

  • Site Reference ID/Investigator# 50153

    Madrid, 28034

Other trials in Spain

New Zealand4 sites
  • Site Reference ID/Investigator# 50126

    Auckland, 1010

  • Site Reference ID/Investigator# 50123

    Christchurch, 8011

  • Site Reference ID/Investigator# 50124

    Hamilton, 3204

  • Site Reference ID/Investigator# 50125

    Wellington, 6002

Other trials in New Zealand

Portugal4 sites
  • Site Reference ID/Investigator# 50136

    Almada, 2805-267

  • Site Reference ID/Investigator# 50134

    Coimbra, 3000-075

  • Site Reference ID/Investigator# 50135

    Lisbon, 1649-035

  • Site Reference ID/Investigator# 50137

    Porto, 4200-319

Other trials in Portugal

Australia3 sites
  • Site Reference ID/Investigator# 46429

    Adelaide, 5000

  • Site Reference ID/Investigator# 46427

    Heidelberg, 3084

  • Site Reference ID/Investigator# 46425

    Westmead, 2145

Other trials in Australia

Canada3 sites
  • Site Reference ID/Investigator# 54545

    Edmonton, T6G 2B7

  • Site Reference ID/Investigator# 46433

    Montreal, H2L 4M1

  • Site Reference ID/Investigator# 46434

    Toronto, M5T 2S8

Other trials in Canada

Poland2 sites
  • Site Reference ID/Investigator# 50140

    Lodz, 93-113

  • Site Reference ID/Investigator# 50139

    Poznan, 61-485

Other trials in Poland

Thailand2 sites
  • Site Reference ID/Investigator# 50150

    Bangkok, 10330

  • Site Reference ID/Investigator# 50151

    Bangkok, 10700

Other trials in Thailand

United Kingdom2 sites
  • Site Reference ID/Investigator# 50149

    Liverpool, L9 7LJ

  • Site Reference ID/Investigator# 50148

    London, WC1N 3BG

Other trials in United Kingdom

Finland1 site
  • Site Reference ID/Investigator# 48003

    Lahti, 15850

Other trials in Finland

Israel1 site
  • Site Reference ID/Investigator# 49882

    Tel Aviv, 64239

Other trials in Israel

Netherlands1 site
  • Site Reference ID/Investigator# 50138

    Nijmegen, 6532 SZ

Other trials in Netherlands

About this study

Official title: An Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects With Advanced Parkinson's Disease and Severe Motor Fluctuations Despite Optimized Treatment With Available Parkinson's Disease Medications

The primary objective of this study will be to provide further evidence of the long-term safety and tolerability of levodopa-carbidopa intestinal gel (Duodopa®) over 12-months in participants with advanced Parkinson's disease (PD) and severe motor fluctuations.

Read the detailed description

The study was composed of a screening period followed by 3 sequential on-treatment periods, as follows:

  • Screening Period (up to 28 days): determination of eligibility and discontinuation of antiparkinsonian disease medications other than levodopa-carbidopa immediate release (LC-oral) prior to nasojejunal (NJ) tube placement.
  • NJ Test Period (2 to 14 days): first hospitalization period, Baseline assessments, placement of NJ tube, and optimization of levodopa-carbidopa intestinal gel (LCIG) treatment via NJ tube and infusion pump (participant was hospitalized for NJ tube placement but hospitalization was not required for entire duration of LCIG treatment optimization).
  • PEG-J Period (2 to 14 days): second hospitalization period; placement of PEG-J tube; further optimization of LCIG treatment.
  • Post PEG-J Long-Term Treatment Period (Day 28 to Day 378): LCIG administration via a permanent PEG-J tube and infusion pump, with dosage adjusted according to clinical condition.
Being tested
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Keywords
severe motor fluctuations, levodopa, levodopa/carbidopa intestinal gel, efficacy, dyskinesia, Parkinson's Disease, carbidopa, DUOPA
Medical subject headings
Dyskinesias, Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Levodopa-carbidopa intestinal gelDrug

    Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).

  • CADD-Legacy® 1400 ambulatory infusion pumpDevice

  • PEG tubeDevice

    percutaneous endoscopic gastrostomy tube

  • J-tubeDevice

    jejunal tube

Study groups in NCT00335153
Study groupRoleWhat they receive
Levodopa-Carbidopa Intestinal Gel (LCIG)ExperimentalAll participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment. The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances.
Receives: Drug: Levodopa-carbidopa intestinal gel; Device: CADD-Legacy® 1400 ambulatory infusion pump; Device: PEG tube; Device: J-tube

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs

    AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.

    Measured: Screening through Day 378 + 30 days

  2. Number of Participants With Device Complications During the Nasojejunal (NJ) Test Period

    Complications of the infusion device were collected during the NJ Test period. Pump, intestinal tube, NJ tube, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.

    Measured: NJ Test Period (from 2 to 14 days)

  3. Number of Participants With Device Complications During the Percutaneous Endoscopic Gastrostomy - With Jejunal Extension Tube (PEG-J) Surgery and Post-PEG Long Term Treatment Periods

    Complications of the infusion device were collected during the PEG-J Surgery and Post-PEG Long-Term Treatment periods. Pump, PEG-J, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and post-procedural hemorrhage.

    Measured: PEG-J Surgery Period (from 2 to 14 days) through the Long Term Treatment Period (Day 28 to Day 378)

  4. Number of Participants With Potentially Clinically Significant Values for Hematology Parameters

    Potentially clinically significant values for red blood cells (RBCs), hemoglobin, and hematocrit are specified for females (f) and males (m) separately in the category rows.

    Measured: Screening through Day 378

  5. Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters

    Terms abbreviated in the table include aspartate aminotransferase (AST), upper limit of normal (ULN), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), female (f), and male (m).

    Measured: Screening through Day 378

  6. Number of Participants With Potentially Clinically Significant Vital Sign Parameters

    Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.

    Measured: up to 56 weeks

  7. Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters

    Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.

    Measured: Screening through Day 378

  8. Number of Participants With Sleep Attacks at Baseline

    To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.

    Measured: Baseline

  9. Number of Participants With Sleep Attacks During the Post-PEG Long-Term Treatment Period

    To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness. Those participants who reported 1 or more sleep attacks were asked to report the number of sleep attacks they experienced, whether they experienced sleepiness or drowsiness prior to the sleep attack, whether they experienced a 'bad' outcome or problem due to a sleep attack, and if so, how many 'bad' outcomes or problems they experienced.

    Measured: During the Post-PEG Long-Term Treatment Period (Day 28 through Day 378)

  10. Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and During the Post-PEG Long-term Treatment (PPLT) Period

    The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.

    Measured: Baseline, during the Post-PEG Long-term Treatment Period (Day 28 through Day 378)

  11. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint

    The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions regarding issues with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia [involuntary muscle movement]).

    Measured: Baseline, Endpoint (last Post-PEG Long-Term Period visit up to Day 378)

  12. Number of Participants With Confirmed Cases of Melanoma

    A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination or end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.

    Measured: Screening up to Day 378

  13. Number of Participants Taking at Least 1 Concomitant Medication During the Study

    Concomitant medications include those started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.

    Measured: Screening up to Day 378

Secondary outcomes (21)
  1. Change From Baseline in Average Daily "Off" Time at Endpoint

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  2. Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  3. Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Endpoint

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  4. Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint

    The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  5. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Month 12

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  6. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  7. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  8. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  9. Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  10. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  11. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  12. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  13. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  14. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  15. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  16. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  17. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  18. Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  19. Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint

    The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  20. Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint

    The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state'.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

  21. Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint

    The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (Range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.

    Measured: Baseline, Endpoint (last post-baseline visit up to Day 378)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2006 (estimated)
  2. Study startJan 2008
  3. Primary completionJun 2012
  4. Study completionJun 2012

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
354 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00335153
Sponsor's protocol ID
S187.3.004
Other IDs
2006-005186-18
Status last verified
Jan 2015
First submitted
8 Jun 2006
Last updated
16 Jan 2015
Data monitoring committee
Yes

Publications

  • Chang FC, Kwan V, van der Poorten D, Mahant N, Wolfe N, Ha AD, Griffith JM, Tsui D, Kim SD, Fung VS. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci. 2016 Mar;25:41-5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14.

    PubMed 26777085
  • Lew MF, Slevin JT, Kruger R, Martinez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015 Jul;21(7):742-8. doi: 10.1016/j.parkreldis.2015.04.022. Epub 2015 Apr 28.

    PubMed 25962554
  • Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24.

    PubMed 25545465

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump and PEG tube in people with Advanced Parkinson's Disease, run by AbbVie (prior sponsor, Abbott) at 83 sites in 16 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Jan 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 83 sites in United States, Germany, Italy, Russia, Czechia and 11 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 16 Jan 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs (time frame: Screening through Day 378 + 30 days). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00335153, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in